F
ibrates are normolipidemic drugs that decrease triglyceride and increase HDL concentrations in humans. 1 Fibrates are efficient drugs for the treatment of specific atherogenic lipid disorders, such as combined hyperlipidemia and hypoalphalipoproteinemia. They exert their effects on plasma lipids by modifying the expression of genes involved in lipoprotein metabolism in the liver. 1 In both rodents and humans, fibrates significantly decrease plasma triglycerides. This triglyceride-lowering activity of fibrates is best explained by the increase of lipoprotein lipase 2 and the decrease of apolipoprotein (apo) C-III 3 gene expression in liver, thereby resulting in enhanced lipolysis of triglyceride-rich particles and subsequent remnant clearance from plasma. The effects of fibrates on HDL metabolism occur primarily via alterations of the expression of the major HDL apolipoproteins, apoA-I and apoA-II, in liver. 4 -6 In contrast to their effects on triglycerides, fibrates influence HDL metabolism in an opposite manner in humans and rodents. In rats, fibrates lower plasma HDL concentrations because of a decrease of liver apoA-I and apoA-II gene expression. 7, 8 In humans, by contrast, fibrates increase plasma HDL by the induction of both human apoA-I and apoA-II gene expression. 4 -6 Fibrates regulate hepatic expression of these genes via activation of peroxisome proliferator-activated receptor-␣ (PPAR␣), a transcription factor belonging to the nuclear receptor family. 1 After ligand activation, PPAR␣ binds to specific response elements, called peroxisome proliferatorresponse elements (PPREs), in the regulatory regions of target genes, thereby regulating their expression. Functional PPREs have been identified in the regulatory regions of the human lipoprotein lipase, apoC-III, apoA-II, and apoA-I genes. 2, 4, 5, 9 In addition to their effects on plasma lipoproteins, fibrates, along with a number of xenobiotic compounds, also induce a pronounced hepatic peroxisome proliferation in rodents, 10, 11 an effect that is mediated via PPAR␣. 12 Peroxisome proliferation involves an increase of size and number of peroxisomes through the induction of specific proteins, most notably the enzymes involved in peroxisomal ␤-oxidation, such as fatty acyl-CoA oxidase (ACO). 13 The peroxisome proliferative response results in a pronounced hepatomegaly and may ultimately lead to hepatocarcinogenesis in rodents, 11 an observation that is of major concern, considering the use of fibrates in the long-term treatment of chronic diseases, such as atherosclerosis, in humans. However, the magnitude of this response appears to vary considerably among species, because rodents are more susceptible to peroxisome proliferation than other species, such as rabbits, nonhuman primates, and humans (rodentsϾrabbitsϾhumans). Because PPAR␣ plays a crucial role in mediating the fibrate response of both lipoprotein metabolism and peroxisome proliferation in rodent species, it is important to determine whether the beneficial effects of fibrates on lipoprotein homeostasis can occur dissociated from a possible deleterious peroxisome proliferation in humans.
In a previous study using transgenic mice overexpressing the human apoA-I gene, we demonstrated that the speciesspecific differences in the response of HDL metabolism to fibrates are due to differences in cis-acting elements between the regulatory regions of the human and mouse apoA-I genes. 6 Because rodents respond to fibrates by a profound peroxisome proliferation and hepatomegaly, which precede the changes in liver apolipoprotein gene expression and the subsequent effects on lipoprotein metabolism, 7, 8 this model did not allow us to establish whether the effects of fibrates on apoA-I and HDL occur independently of their effects on peroxisome proliferation. Therefore, we studied the effects of fibrates on apoA-I expression in rabbits, which, like humans, are more resistant to peroxisome proliferation. 14 Our results demonstrate that fibrate treatment does not influence serum apoA-I concentrations in normal rabbits. Therefore, we went on to use a transgenic rabbit model that expresses the human apoA-I gene under control of its homologous regulatory regions, including the fibrate-response elements previously shown to be active in mice. 6 We show that treatment with fenofibrate increases serum concentrations and liver mRNA levels of human apoA-I in these rabbits. These effects occur without any hepatomegaly or induction of peroxisomal ACO expression and activity in liver, indicating that the beneficial effects of fibrates on lipoprotein metabolism do not require a simultaneous induction of peroxisomal enzyme activities and therefore occur independently.
Methods

Animals
All animal studies were conducted in accordance with institutional guidelines. New Zealand White (NZW) and human apoA-I transgenic rabbits 15 were randomized on serum HDL cholesterol and human apoA-I concentrations. Animals were treated daily with fenofibrate (Fournier) mixed with standard chow as indicated. Body weights and food intake were recorded daily. Blood was collected after an overnight fast, and serum was separated and kept at 4°C until analysis. Animals were killed by exsanguination under barbital anesthesia. Tissues were removed, weighed, frozen in liquid nitrogen, and stored until analysis.
Serum Lipid, Apolipoprotein, and Lipoprotein Measurements
Serum triglycerides, total cholesterol, and HDL cholesterol were measured with kits from Boehringer Mannheim. Rabbit apoA-I in nontransgenic animals and total (human and rabbit) apoA-I in transgenic rabbits were quantified by an immunonephelometric assay. 15 Human apoA-I concentrations were specifically quantified with polyclonal antibodies raised in rabbit. Interassay coefficients of variation for cholesterol and apolipoproteins ranged from 1.5% to 6.2%.
Lipoprotein fractions (VLDL, dϽ1.006 g/mL; IDLϩLDL, dϭ1.006 to 1.063 g/mL; HDL, dϭ1.063 to 1.21 g/mL) were isolated by sequential ultracentrifugation, and lipoprotein lipid and protein content were measured.
HDL size was determined by nondenaturing gel electrophoresis on 4% to 20% polyacrylamide gradient gels (Novex). Thyroglobulin (665 kDa), ferritin (440 kDa), catalase (232 kDa), lactate dehydrogenase (140 kDa), and albumin (67 kDa) were used as calibrating proteins.
RNA Analysis
RNA isolation and Northern blot analysis were performed with human apoA-I, rat ACO, and chicken ␤-actin cDNA probes. 6 mRNA levels were analyzed by quantitative scanning densitometry (Biorad GS670 Densitometer) and normalized for actin levels.
Measurement of Liver ACO Activities
Livers were homogenized in ice-cold sucrose solution (0.25 mol/L sucrose in 10 mmol/L HEPES buffer and 1 mmol/L EDTA, pH 7.4), and ACO activity was determined. 16 
Statistical Analysis
The data from the 3 groups of animals were compared at each time by ANOVA with the Statview program. When the F ratio was significant (PϽ0.05), Wilcoxon paired tests and Mann-Whitney tests were used for intragroup and intergroup comparisons, respectively.
Results
Fenofibrate Does Not Influence Liver Weight or ApoA-I Expression in Rabbits
Because the effects of fibrates on serum lipids and, in particular, on serum HDL cholesterol and apoA-I concentrations in rabbits have been poorly characterized, NZW rabbits were treated for 2 weeks with fenofibrate (mixed with chow at 0.625%; consumed doses ranging from 100 to 250 mg
, and serum lipids were measured before and after the treatment period. Serum total cholesterol increased significantly in the fenofibrate-treated animals because of an increase of cholesterol in both HDL and non-HDL particles ( Figure 1 ). Indeed, the HDL/total cholesterol ratio was similar in treated and control animals. Serum triglyceride and apoA-I concentrations did not change after fenofibrate (Figure 1) . Fenofibrate treatment did not influence intestinal mRNA levels of apoA-I (Figure 1 ), whose expression, in contrast to that in humans and rodents, is restricted to the intestine. 17 Therefore, the variations in serum cholesterol concentrations after fenofibrate treatment occur independently of transcriptional modulation of apoA-I gene expres-sion. Furthermore, liver weights did not change after fenofibrate administration (control, 2.50Ϯ0.49% versus treated, 2.38Ϯ0.17% of body weight), indicating that the rabbit does not develop hepatomegaly at doses that induce hepatomegaly in rats. 8 
Fenofibrate Increases Serum Concentrations of HDL and Human ApoA-I in Human ApoA-I Transgenic Rabbits
To determine whether the presence of the human apoA-I transgene could confer responsiveness to fibrates in rabbits, human apoA-I transgenic rabbits were treated with fenofibrate (250 mg ⅐ kg
) for 3 weeks, and serum concentrations of human apoA-I were measured weekly. In contrast to untreated transgenic rabbits, whose serum human apoA-I concentrations remained constant throughout the entire treatment period, fenofibrate treatment increased human apoA-I Ͼ2-fold after 1 week of treatment. Thereafter, human apoA-I concentrations remained constant, indicating that a steady state is obtained within 7 days of fenofibrate treatment ( Figure 2) .
Next, a dose-response experiment was performed. Human apoA-I transgenic rabbits were treated for 12 days, at which time maximal effects on human apoA-I are already observed (Figure 2 ), with either 125 or 250 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 of fenofibrate, and the changes in serum total and HDL cholesterol, triglyceride, and human apoA-I concentrations were analyzed. None of the treatments significantly influenced body weight (Table 1) or food intake of the rabbits (data not shown). Serum human apoA-I levels significantly increased in a dose-dependent manner (Table 2 and Figure 3 ). Whereas total and HDL cholesterol concentrations decreased slightly in the untreated rabbits, they increased significantly after fenofibrate (Table 2 and Figure 3 ). The changes in HDL cholesterol were paralleled by similar changes in serum phospholipids, whereas triglycerides did not change significantly (data not shown). Because total and HDL cholesterol concentrations increased to the same extent, the increase in total cholesterol appeared to be due primarily to the rise of HDL concentrations after fenofibrate. Nondenaturing gradient gel electrophoresis analysis revealed no major change in HDL size distribution after fenofibrate (Figure 4) . Furthermore, HDL particle composition did not differ significantly between control and fenofibrate-treated animals (data not shown). Thus, fenofibrate increases the number of HDL particles without affecting their size or composition.
Fenofibrate Induces Liver Human ApoA-I Without Changing Intestinal Rabbit ApoA-I Gene Expression
To determine whether the effects of fenofibrate on serum HDL and human apoA-I were associated with alterations in rabbit or human apoA-I gene expression, RNA was extracted from livers and intestines and apoA-I mRNA levels were measured by Northern blot analysis. As in normal rabbits (Figure 1 ), fenofibrate did not influence intestinal rabbit apoA-I gene expression ( Figure 5 ). By contrast, human apoA-I mRNA levels increased significantly in liver after fenofibrate (Figures 5 and 6) . As a control, neither intestinal or liver actin mRNA levels changed after fenofibrate treatment ( Figure 5 ). Northern blot analysis indicated the presence of a single PPAR␣ message of Ϸ8 kb expressed predominantly in liver and to a lesser extent in intestine, but fenofibrate did not influence PPAR␣ mRNA levels in either tissue (data not shown).
Fenofibrate Does Not Influence Liver Weight or Peroxisomal ACO Activity and mRNA Levels in Human ApoA-I Transgenic Rabbits
To determine whether the effects of fenofibrate on serum HDL and apoA-I metabolism occur independently of any peroxisome stimulation, mRNA levels and enzyme activity of Influence of fenofibrate (FF) on serum human apoA-I concentrations in human apoA-I transgenic rabbits. Rabbits were treated daily for 3 weeks with fenofibrate (mixed at 0.625% in rabbit chow, nϭ2) or chow (Control, nϭ2). Serum was isolated at indicated time points, and human apoA-I concentrations were measured.
ACO, the rate-limiting enzyme in the peroxisomal ␤-oxidation pathway and a sensitive marker for the PPARmediated peroxisome proliferative response to fibrates in rodents, 12, 13, 18 were measured in human apoA-I transgenic rabbits treated for 12 days with fenofibrate. Compared with untreated rabbits, fenofibrate did not significantly increase liver ACO activity or mRNA levels (Table 1) . Furthermore, this treatment did not induce hepatomegaly (Table 1) , as in normal rabbits. Therefore, the induction of apoA-I expression by fibrates and its consequences on HDL metabolism occur independently of any peroxisome proliferative response.
Discussion
Clinical studies in humans have demonstrated that fibrates exert an inductive action on plasma concentrations of HDL, a protective factor against atherosclerosis development. 19 Results from both in vitro 4, 5 and in vivo studies using transgenic human apoA-I mice 6 indicate that this HDL induction occurs, in large part, via an increased expression of its major apolipoprotein constituents, apoA-I and apoA-II. Furthermore, the induction of apoA-I and apoA-II expression by fibrates occurs primarily at the transcriptional level and is mediated via PPAR␣ binding to PPREs in the human apoA-I and apoA-II gene regulatory regions. 4, 5 However, because PPAR␣ also mediates the undesirable peroxisome proliferative response to fibrates in rodents 12 and because most studies on the effects of fibrates on apolipoprotein gene expression have been performed in in vitro model systems or in vivo in rodents, 1 it remains highly controversial whether the beneficial effects on plasma lipoprotein metabolism could occur independently of a potential hazardous induction of peroxisomal activity. In the present study, we addressed this issue using the rabbit as a model for 2 reasons. First, like humans, rabbits have been reported to be much less responsive to peroxisome proliferators than rodents. 14 Second, our laboratories have recently established a transgenic rabbit that overexpresses the human apoA-I gene under control of its homologous promoter, including the fibrate-response elements. 15 These rabbits express the human apoA-I gene exclusively in the liver, the site of fibrate action, and carry serum apoA-I concentrations comparable to those in humans. 15 In a first experiment using high concentrations of fenofibrate, we demonstrated that normal, nontransgenic rabbits are nonresponsive to fibrate treatment with respect to serum triglyceride and apoA-I concentrations and intestinal apoA-I mRNA levels. The reason why rabbits do not respond to fibrate treatment is unclear at present. Because we (data not shown) and others 20 could demonstrate the presence of PPAR␣ expression in rabbit liver and because the human apoA-I transgene is responsive to fibrate treatment in rabbits, absence of functional PPAR␣ expression seems an unlikely explanation. It is more likely that the absence in rabbit liver of expression of specific PPAR␣ target genes, such as apoA-I Human apoA-I transgenic rabbits were treated with fenofibrate for 12 days. Serum lipid and human apoA-I concentrations were measured at beginning (day 0) and end (day 12) of the treatment period and expressed as meanϮSD. ANOVAs between control and both treated groups at baseline were not significantly different. After day 12, ANOVAs between the 3 groups indicated significant differences (Pϭ0.0273 for total cholesterol, Pϭ0.0349 for HDL cholesterol, and Pϭ0.0001 for human apoA-I). Only significant differences between groups are indicated.
*Wilcoxon test for paired data vs corresponding baseline. †Mann-Whitney test vs control at day 12. ‡Mann-Whitney test vs low-dose group at day 12. §PϽ0.05; PϽ0.01.
and apoA-II, 21 precludes a fibrate response on these genes in this species. Indeed, in rabbits, apoA-I expression is limited to the intestine, 17 and fibrates regulate the expression of apolipoproteins, such as apoA-I and apoA-IV, in the liver and not in the intestine of rats. 7, 22 In addition, differences between species leading to the presence or absence of functional PPREs in the regulatory regions of genes controlling lipid and lipoprotein homeostasis may contribute to species-specific differences in response to fibrates. Indeed, the absence of a functional PPRE in the rat apoA-I gene promoter contributes to the absence of induction of apoA-I expression in this species after fibrate treatment. 23 In humans or in human apoA-I transgenic mice, 6 the elevation of HDL cholesterol after fibrate treatment could be attributed partially to enhanced lipolysis of triglyceride-rich lipoproteins and redistribution of lipid components from these particles to HDL. However, no effect on triglyceride concentrations occurs in fibrate-fed normal or transgenic rabbits. In contrast, fenofibrate treatment resulted in a significant induction of serum total cholesterol concentrations, which was associated with an increase of HDL cholesterol and human apoA-I concentrations. Furthermore, the HDL particles in fenofibrate-treated rabbits were of a size and composition similar to those in untreated transgenic rabbits, suggesting an increased production of HDL rather than alterations in intravascular HDL remodeling after fibrate treatment. These data indicate that, at least in rabbits, the HDL-inductive effects of fibrates are due to the induction of apoA-I expression and occur independently of any triglyceride-lowering activity.
The increase of serum human apoA-I concentrations was associated with a comparable induction of human apoA-I mRNA levels in liver. In mice, a disproportionate higher induction of plasma HDL concentrations is observed after fibrate treatment. 6 In contrast to rodents, rabbits carry a significant portion of their plasma cholesterol in LDL and have high plasma cholesteryl ester transfer protein (CETP) activity, similar to that in humans. 24 It is tempting to speculate that the absence of CETP expression in mice results in an interrupted HDL metabolism that is exacerbated after fibrate treatment. Thus, human apoA-I transgenic rabbits may be a better model than mice for the study of HDL regulation by PPAR␣ and other activators, because they more closely resemble the human situation. Figure 3 . Serum HDL was isolated by ultracentrifugation, and HDL protein (10 g) from control and fenofibrate-treated rabbits was separated by nondenaturing gradient gel electrophoresis. Figure 5 . Effects of fenofibrate (FF) on liver and intestinal human and rabbit apoA-I mRNA levels in human apoA-I transgenic rabbits. Total RNA was extracted from livers and intestines from transgenic rabbits treated as in Figure 3 , and mRNA levels were measured. *Statistically (Mann-Whitney test, PϽ0.01) significant differences. R.A.U. indicates relative arbitrary units. Figure 6 . Northern blot analysis of effects of fenofibrate 250 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 on human apoA-I mRNA levels in livers of human apoA-I transgenic rabbits. Human apoA-I transgenic rabbits were treated as in Figure 3 , total RNA was extracted from liver, and Northern blot analysis was performed.
The major finding of this study is that serum HDL and human apoA-I increase in human apoA-I transgenic rabbits without any hepatomegaly, indicating that the beneficial effects of fibrates on lipoprotein metabolism occur independently of any deleterious effect on peroxisome proliferation. These results confirm previous studies indicating that rabbits are much less sensitive to peroxisome proliferation than rodents 6, 8 and more closely resemble the human situation. 14 In addition, the absence of hepatomegaly is accompanied by a lack of induction of enzymes of peroxisomal ␤-oxidation, such as ACO, whereas serum HDL and human apoA-I concentrations increase significantly after fenofibrate. These observations are in contrast to the situation in rats and (transgenic) mice, in which fenofibrate at doses comparable to those used in this study increases liver weight by Ͼ2-fold. 6, 8 Furthermore, in rats, peroxisomal ACO activity increases to 225% already after a shorter period (5 days) and at lower doses (125 mg ⅐ kg Ϫ1 ⅐ d
Ϫ1
) of fenofibrate, and 5-to 10-fold increases are observed after 2 weeks. 25 In primary rat hepatocytes, ACO gene induction by fenofibrate precedes its effects on apolipoprotein gene expression, 7 making it impossible to evaluate whether the effects of fibrates on lipoprotein metabolism occur independently of changes in peroxisomal enzyme activities. Here, we show that the induction of human apoA-I gene expression by fibrates occurs independently of any peroxisome proliferative response in vivo. These data extend previous studies in humans suggesting that the hypolipidemic action of fibrates is linked to an increase in mitochondrial but not peroxisomal volume density. 26 Furthermore, previous studies in humans revealed no effects of fibrates on liver volume and no influence of fenofibrate or gemfibrozil on liver peroxisomes, whereas clofibrate slightly increased peroxisome number but not size. 26 -28 Furthermore, fibrates do not induce a peroxisome proliferation in human hepatocytes. 3, 29 Moreover, in human hepatoma HepG2 cells, ciprofibrate treatment did not influence cell morphology or proliferation or ACO activity, whereas rat Fao hepatoma cells responded positively in all these parameters. 30, 31 Several hypotheses can be offered to explain the absence of peroxisome proliferation in humans. These include speciesspecific differences in the expression level of PPAR␣ or its cofactors in liver (rodentsϾhumans), differences in ligand specificity of human versus rodent PPAR␣ leading to a lower response of human PPAR␣ to certain peroxisome proliferators but not to fibrates, and differences in target gene specificity. Indeed, the presence/absence of PPREs in target gene regulatory sequences in the apoA-I gene 6,23 may lead to differences in response between species.
In conclusion, the presence of the human apoA-I transgene is sufficient to confer apoA-I responsiveness to fibrate treatment. Because hepatic peroxisomal enzyme activities are impossible to measure in patients on fibrate therapy, our data obtained in transgenic apoA-I rabbits provide in vivo evidence that the beneficial effects of fibrates on serum lipoprotein metabolism can occur independently of any deleterious peroxisome proliferative effect. Together with several decades of clinical experience showing no evidence of an increased incidence of hepatocarcinogenicity in humans, our results indicate that fibrates should be considered safe drugs with respect to peroxisome proliferation and possibly hepatocarcinogenesis.
